Pictet Asset Management (Switzerland)’s Axsome Therapeutics AXSM Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$33.3M	Buy	463,842 +460,534	+13,922%	+$34M	0.04%	358
2023 Q1	$204K	Hold	3,308	–	–	﹤0.01%	1726
2022 Q4	$255K	Buy	+3,308	New	+$198K	﹤0.01%	1579
2022 Q3	–	Sell	-353,521	Closed	-$13.5M	–	1572
2022 Q2	$13.5M	Buy	353,521 +171,849	+95%	+$5.43M	0.02%	529
2022 Q1	$7.52M	Sell	181,672 -121,159	-40%	-$3.76M	0.01%	719
2021 Q4	$11.4M	Buy	+302,831	New	+$11.1M	0.01%	636

Other funds holding AXSM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s AXSM Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Axsome Therapeutics (AXSM) stake by 13,922% in Q2 2023, buying an estimated $34M and bringing the position to 463,842 shares worth $33.3M. The position accounts for 0.04% of the portfolio, ranked #358.

Pictet Asset Management (Switzerland) first reported a position in AXSM in Q4 2021 and has held it in 6 quarters since. 231 funds tracked by Wall St. Rank hold AXSM as of Q2 2023.

Pictet Asset Management (Switzerland) held 463,842 shares of Axsome Therapeutics worth $33.3M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 460,534 Axsome Therapeutics shares in Q2 2023, an estimated $34M.
Axsome Therapeutics made up 0.04% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #358 holding.
Pictet Asset Management (Switzerland) first reported a position in Axsome Therapeutics in Q4 2021 and has held it in 6 quarters since.
231 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.